Avantor (AVTR) Launches Solutions for Gene Therapy Harvest

Company Developments - Avantor, Inc. has launched two innovative products, J.T.Baker Cell Lysis Solution and J.T.Baker Endonuclease, aimed at improving the gene therapy harvest process, enhancing efficiency, and reducing environmental impact [1][2] - The J.T.Baker Cell Lysis Solution is an eco-friendly alternative to Octoxynol-9, designed to be biodegradable and exhibit low ecotoxicity, aligning with global sustainability goals and REACH regulations [2] - The combination of J.T.Baker Cell Lysis Solution and J.T.Baker Endonuclease streamlines the harvest process by effectively removing impurities and reducing aggregation, thus enhancing productivity and maintaining the quality of viral particles [3] Industry Insights - The global gene therapy market is projected to grow from an estimated $10.47 billion to $52.40 billion by 2033, reflecting a compound annual growth rate (CAGR) of 19.6% [4] - Facility expansion for cell and gene therapies is a key driver of market growth, with increased investments in production capacity from in-house facilities and CDMOs [4] Recent Leadership Changes - Avantor appointed Corey Walker as president of Laboratory Solutions, leveraging his industry knowledge and familiarity with the organization to lead the business effectively [5] Stock Performance - Avantor's shares have declined by 9% year-to-date, contrasting with a 3.6% rise in the industry and a 15% increase in the S&P 500 during the same period [6]